PLYX

Polaryx TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$1.75

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-28

AI commentary

The packet contains no recent news or social aggregate and no usable analyst-revision dataset, so sentiment is primarily filing-driven. The July 27 anchor price of $1.96 remains well below the May financing price near $4.00. A CEO Form 4 reported an open-market purchase of 88,453 shares at $4.07, but insider activity is not evidence of operating performance. [#SEC-FORM4-2026-05-28] Overall, the setup is asymmetric but low-visibility and best treated as cautious monitoring.

RankAlpha Sentiment Codex - 2026-07-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystRunway and dilution remain the near-term trading driverHigh impact

The May private placement raised $10 million gross at an approximately $4.00 weighted-average price to fund SOTERIA and working capital, but the March 31 filing showed only $3.08 million of cash, no product revenue, recurring losses, and funding visibility through the third quarter of 2026. The financing improves flexibility but does not eliminate follow-on funding and dilution risk. [#SEC-10Q-2026-05-15] [#SEC-8K-2026-05-28]

2026-12-31eventSOTERIA Phase 2 initiation in the second half of 2026High impact

PLX-200's Phase 2 proof-of-concept basket trial, SOTERIA, is expected to begin in the second half of 2026. The company reports that the FDA IND was submitted in August 2025 and received a safe-to-proceed letter in October 2025. On-time initiation and early enrollment would be the clearest near-term execution de-risking event. [#10-K-2026-03-24] [#SEC-10Q-2026-05-15]

2027-12-31catalystClinical readthrough could establish registrable paths across four indicationsHigh impact

SOTERIA covers CLN2, CLN3, Krabbe disease, and Sandhoff disease, with company commentary indicating that data could guide potentially registrable trials or expedited-approval discussions. This offers substantial upside, but visibility remains low until enrollment and clinical efficacy are demonstrated. [#10-K-2026-03-24]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-28 • Updated nightlySource: Internal modelMethodology